This report is from a non-medical psychedelic retreat centre documenting participant responses to a series of surveys on continuing benefits for depression and anxiety symptoms.

Ketamine and its chemical derivative, esketamine, have the ability to alleviate severe depression almost instantly, particularly in cases resistant to other treatments. This represents a significant breakthrough in psychiatry. However, a complex mix of economic, regulatory, and research barriers have resulted in these potentially life-saving treatments remaining out of reach for many patients with severe depression.

These findings suggest that an acute low dose of LSD (26 µg) elicits more pronounced positive mood and stimulant-like effects, as well as stronger altered states of consciousness in individuals with depressive symptoms, compared to non-depressed individuals.

Ketamine has the potential to change our approach to the clinical management of depression if knowledge, attitudinal, and regulatory barriers can be overcome, and if risks related to comorbidities and concurrent medications are addressed by close supervision.

Ketamine may have antidepressant properties, but its acute psychoactive effects complicate successful masking in placebo-controlled trials

In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week 8.

The potentially enhanced efficacy effect of a DMT-based treatment when administered with SSRIs could lead to greater therapeutic benefit for [major depressive disorder (MDD)] patients.

Our integrative model aims to bridge the biomedical-psychedelic divide to offer a feasible, flexible, and standardized approach to ketamine for TRD. Our learnings from developing and implementing this psychedelic-inspired model for severe, real-world patients in two academic hospitals may offer valuable insights for the ongoing roll-out of a range of psychedelic therapies.

Psilocybin treatment was associated with a clinically significant sustained reduction in depressive symptoms and functional disability, without serious adverse events.

Our findings suggested that effect sizes for depression severity, as well as response and remission rates, were numerically greater for racemic ketamine than esketamine.

We conducted a systematic review and a dose-response meta-analysis to find the optimal dosage of psilocybin.

Abstracts of the 31st European Congress of Psychiatry

Administration of GH001 to a cohort of 16 patients with TRD was well tolerated and provided potent and ultra-rapid antidepressant effects.

Ketamine was associated with comparable clinical benefits, safety, and tolerability in a TAY sample as compared to a matched GA TRD sample.

Psilocybin has the potential to be a cost-effective therapy for severe depression. This depends on the level of psychological support that is given to patients receiving psilocybin and the price of the drug itself. Further data on long-term outcomes are required to improve the evidence base.